Copy to clipboard 
DJO Global posted 1Q17 revenue of US $288.4MM, +3.4% vs. 1Q16.
ORTHOWORLD estimates segment sales and growth on an as-reported basis as follows:
| 1Q17 | 1Q16 | $ Change | % Change | |
| Joint Reconstruction | $60.2 | $50.6 | $9.6 | 19.0% |
| Knee | $16.0 | $13.2 | $2.8 | 21.3% |
| Hip | $14.5 | $11.5 | $3.0 | 25.9% |
| Extremities | $29.7 | $25.9 | $3.8 | 14.8% |
| Other* | $228.2 | $228.3 | -$0.1 | -0.1% |
| Total | $288.4 | $278.9 | $9.5 | 3.4% |
*Includes Bracing/Vascular, Recovery Sciences and also International revenue not already attributed to Joint Recon
1Q17 performance highlights:
- Strong growth in Surgical Implant (Joint Recon) attributed to product launches and an experienced, growing sales team
- Leadership notes >20% organic growth across all joint recon implant lines
- At AAOS 2017, launched AltiVate anatomic shoulder and EXPRT revision hip
- After quarter’s close, partnered with IPG on delivery of its range of Surgical Implant products; IPG provides Device Benefit Management programs to health plan clients and patients
Business transformation update:
- Fully executing as of 1Q, with positive momentum
- On target for 1Q planned cost-savings and liquidity improvements, maintained reduced inventory levels
- Replacing ~1/2 of the top 30 leadership roles and numerous key leaders in the next level; new hires include VPs and SVPs in roles of Global Customer Experience/Sales Operations, Reimbursement/Revenue Cycle, Payor Development, Operations Finance, Transformation for Global Quality and Operations, etc.
Sources: DJO Global, Inc.; ORTHOWORLD estimates
DJO Global posted 1Q17 revenue of US $288.4MM, +3.4% vs. 1Q16.
ORTHOWORLD estimates segment sales and growth on an as-reported basis as follows:
Q17
Q16
$ Change
% Change
Joint Reconstruction
$60.2
$50.6 ...
DJO Global posted 1Q17 revenue of US $288.4MM, +3.4% vs. 1Q16.
ORTHOWORLD estimates segment sales and growth on an as-reported basis as follows:
| 1Q17 | 1Q16 | $ Change | % Change | |
| Joint Reconstruction | $60.2 | $50.6 | $9.6 | 19.0% |
| Knee | $16.0 | $13.2 | $2.8 | 21.3% |
| Hip | $14.5 | $11.5 | $3.0 | 25.9% |
| Extremities | $29.7 | $25.9 | $3.8 | 14.8% |
| Other* | $228.2 | $228.3 | -$0.1 | -0.1% |
| Total | $288.4 | $278.9 | $9.5 | 3.4% |
*Includes Bracing/Vascular, Recovery Sciences and also International revenue not already attributed to Joint Recon
1Q17 performance highlights:
- Strong growth in Surgical Implant (Joint Recon) attributed to product launches and an experienced, growing sales team
- Leadership notes >20% organic growth across all joint recon implant lines
- At AAOS 2017, launched AltiVate anatomic shoulder and EXPRT revision hip
- After quarter’s close, partnered with IPG on delivery of its range of Surgical Implant products; IPG provides Device Benefit Management programs to health plan clients and patients
Business transformation update:
- Fully executing as of 1Q, with positive momentum
- On target for 1Q planned cost-savings and liquidity improvements, maintained reduced inventory levels
- Replacing ~1/2 of the top 30 leadership roles and numerous key leaders in the next level; new hires include VPs and SVPs in roles of Global Customer Experience/Sales Operations, Reimbursement/Revenue Cycle, Payor Development, Operations Finance, Transformation for Global Quality and Operations, etc.
Sources: DJO Global, Inc.; ORTHOWORLD estimates
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
